Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Provided By GlobeNewswire
Last update: Sep 10, 2025
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability
Read more at globenewswire.comNASDAQ:RVMD (12/8/2025, 1:29:06 PM)
79.045
-0.59 (-0.75%)
Find more stocks in the Stock Screener
